EUROFINS SCIENTIFIC (ERF.PA) Stock Fundamental Analysis
Europe - EPA:ERF - FR0014000MR3 - Common Stock
62.7 EUR
+0.06 (+0.1%)
Overall ERF gets a fundamental rating of 5 out of 10. We evaluated ERF against 21 industry peers in the Life Sciences Tools & Services industry. ERF has an average financial health and profitability rating. ERF is valued quite cheap, while showing a decent growth score. This is a good combination!
1. Profitability
1.1 Basic Checks
ERF had positive earnings in the past year.
In the past year ERF had a positive cash flow from operations.
In the past 5 years ERF has always been profitable.
In the past 5 years ERF always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of ERF (3.54%) is comparable to the rest of the industry.
With a decent Return On Equity value of 8.09%, ERF is doing good in the industry, outperforming 66.67% of the companies in the same industry.
The Return On Invested Capital of ERF (9.79%) is better than 85.71% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ERF is in line with the industry average of 7.48%.
The 3 year average ROIC (8.70%) for ERF is below the current ROIC(9.79%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.54% | ||
| ROE | 8.09% | ||
| ROIC | 9.79% |
ROA(3y)3.79%
ROA(5y)5.05%
ROE(3y)7.94%
ROE(5y)10.72%
ROIC(3y)8.7%
ROIC(5y)10.54%
1.3 Margins
With a Profit Margin value of 5.44%, ERF is not doing good in the industry: 61.90% of the companies in the same industry are doing better.
In the last couple of years the Profit Margin of ERF has grown nicely.
With a Operating Margin value of 15.59%, ERF perfoms like the industry average, outperforming 47.62% of the companies in the same industry.
ERF's Operating Margin has improved in the last couple of years.
ERF's Gross Margin of 23.29% is on the low side compared to the rest of the industry. ERF is outperformed by 80.95% of its industry peers.
In the last couple of years the Gross Margin of ERF has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.59% | ||
| PM (TTM) | 5.44% | ||
| GM | 23.29% |
OM growth 3Y-11.93%
OM growth 5Y3.56%
PM growth 3Y-23.05%
PM growth 5Y9.75%
GM growth 3Y-7.6%
GM growth 5Y1.83%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ERF is still creating some value.
Compared to 1 year ago, ERF has less shares outstanding
ERF has more shares outstanding than it did 5 years ago.
ERF has a better debt/assets ratio than last year.
2.2 Solvency
ERF has an Altman-Z score of 2.71. This is not the best score and indicates that ERF is in the grey zone with still only limited risk for bankruptcy at the moment.
ERF has a Altman-Z score (2.71) which is in line with its industry peers.
ERF has a debt to FCF ratio of 5.25. This is a neutral value as ERF would need 5.25 years to pay back of all of its debts.
ERF has a Debt to FCF ratio of 5.25. This is in the better half of the industry: ERF outperforms 71.43% of its industry peers.
ERF has a Debt/Equity ratio of 0.77. This is a neutral value indicating ERF is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.77, ERF is doing worse than 71.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.77 | ||
| Debt/FCF | 5.25 | ||
| Altman-Z | 2.71 |
ROIC/WACC1.26
WACC7.74%
2.3 Liquidity
ERF has a Current Ratio of 1.26. This is a normal value and indicates that ERF is financially healthy and should not expect problems in meeting its short term obligations.
ERF has a worse Current ratio (1.26) than 61.90% of its industry peers.
ERF has a Quick Ratio of 1.19. This is a normal value and indicates that ERF is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.19, ERF is in line with its industry, outperforming 52.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.26 | ||
| Quick Ratio | 1.19 |
3. Growth
3.1 Past
ERF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.50%, which is quite good.
Measured over the past years, ERF shows a quite strong growth in Earnings Per Share. The EPS has been growing by 18.34% on average per year.
Looking at the last year, ERF shows a small growth in Revenue. The Revenue has grown by 2.53% in the last year.
Measured over the past years, ERF shows a quite strong growth in Revenue. The Revenue has been growing by 8.78% on average per year.
EPS 1Y (TTM)16.5%
EPS 3Y-21.42%
EPS 5Y18.34%
EPS Q2Q%19.61%
Revenue 1Y (TTM)2.53%
Revenue growth 3Y1.14%
Revenue growth 5Y8.78%
Sales Q2Q%5.64%
3.2 Future
ERF is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.34% yearly.
Based on estimates for the next years, ERF will show a small growth in Revenue. The Revenue will grow by 7.27% on average per year.
EPS Next Y14.76%
EPS Next 2Y14.31%
EPS Next 3Y14.14%
EPS Next 5Y13.34%
Revenue Next Year5.44%
Revenue Next 2Y5.6%
Revenue Next 3Y6.01%
Revenue Next 5Y7.27%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ERF is valuated rather expensively with a Price/Earnings ratio of 17.42.
Based on the Price/Earnings ratio, ERF is valued cheaper than 90.48% of the companies in the same industry.
When comparing the Price/Earnings ratio of ERF to the average of the S&P500 Index (27.67), we can say ERF is valued slightly cheaper.
Based on the Price/Forward Earnings ratio of 15.53, the valuation of ERF can be described as correct.
Based on the Price/Forward Earnings ratio, ERF is valued cheaply inside the industry as 90.48% of the companies are valued more expensively.
ERF's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.33.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.42 | ||
| Fwd PE | 15.53 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ERF is valued cheaply inside the industry as 90.48% of the companies are valued more expensively.
95.24% of the companies in the same industry are more expensive than ERF, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.57 | ||
| EV/EBITDA | 8.69 |
4.3 Compensation for Growth
ERF's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ERF has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ERF's earnings are expected to grow with 14.14% in the coming years.
PEG (NY)1.18
PEG (5Y)0.95
EPS Next 2Y14.31%
EPS Next 3Y14.14%
5. Dividend
5.1 Amount
With a yearly dividend of 0.95%, ERF is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 0.69, ERF pays a better dividend. On top of this ERF pays more dividend than 85.71% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.35, ERF's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.95% |
5.2 History
The dividend of ERF is nicely growing with an annual growth rate of 16.51%!
Dividend Growth(5Y)16.51%
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
54.91% of the earnings are spent on dividend by ERF. This is a bit on the high side, but may be sustainable.
ERF's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP54.91%
EPS Next 2Y14.31%
EPS Next 3Y14.14%
EPA:ERF (10/24/2025, 1:19:39 PM)
62.7
+0.06 (+0.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners37.21%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap11.42B
Revenue(TTM)6.89B
Net Income(TTM)374.80M
Analysts68.89
Price Target65.1 (3.83%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.95% |
Yearly Dividend0.52
Dividend Growth(5Y)16.51%
DP54.91%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)7.84%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.22%
EPS NY rev (3m)-0.46%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.26%
Revenue NY rev (3m)-0.82%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.42 | ||
| Fwd PE | 15.53 | ||
| P/S | 1.66 | ||
| P/FCF | 14.57 | ||
| P/OCF | 8.69 | ||
| P/B | 2.46 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.69 |
EPS(TTM)3.6
EY5.74%
EPS(NY)4.04
Fwd EY6.44%
FCF(TTM)4.3
FCFY6.87%
OCF(TTM)7.22
OCFY11.51%
SpS37.84
BVpS25.45
TBVpS-3.69
PEG (NY)1.18
PEG (5Y)0.95
Graham Number45.4
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.54% | ||
| ROE | 8.09% | ||
| ROCE | 12.64% | ||
| ROIC | 9.79% | ||
| ROICexc | 10.74% | ||
| ROICexgc | 34.1% | ||
| OM | 15.59% | ||
| PM (TTM) | 5.44% | ||
| GM | 23.29% | ||
| FCFM | 11.37% |
ROA(3y)3.79%
ROA(5y)5.05%
ROE(3y)7.94%
ROE(5y)10.72%
ROIC(3y)8.7%
ROIC(5y)10.54%
ROICexc(3y)9.52%
ROICexc(5y)11.6%
ROICexgc(3y)31.02%
ROICexgc(5y)39.55%
ROCE(3y)11.31%
ROCE(5y)13.7%
ROICexgc growth 3Y-18.17%
ROICexgc growth 5Y3.78%
ROICexc growth 3Y-15.5%
ROICexc growth 5Y6.63%
OM growth 3Y-11.93%
OM growth 5Y3.56%
PM growth 3Y-23.05%
PM growth 5Y9.75%
GM growth 3Y-7.6%
GM growth 5Y1.83%
F-Score7
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.77 | ||
| Debt/FCF | 5.25 | ||
| Debt/EBITDA | 2.1 | ||
| Cap/Depr | 84.94% | ||
| Cap/Sales | 7.7% | ||
| Interest Coverage | 9.93 | ||
| Cash Conversion | 77.37% | ||
| Profit Quality | 209.21% | ||
| Current Ratio | 1.26 | ||
| Quick Ratio | 1.19 | ||
| Altman-Z | 2.71 |
F-Score7
WACC7.74%
ROIC/WACC1.26
Cap/Depr(3y)89.21%
Cap/Depr(5y)85.64%
Cap/Sales(3y)8.63%
Cap/Sales(5y)7.99%
Profit Quality(3y)162.79%
Profit Quality(5y)158.88%
High Growth Momentum
Growth
EPS 1Y (TTM)16.5%
EPS 3Y-21.42%
EPS 5Y18.34%
EPS Q2Q%19.61%
EPS Next Y14.76%
EPS Next 2Y14.31%
EPS Next 3Y14.14%
EPS Next 5Y13.34%
Revenue 1Y (TTM)2.53%
Revenue growth 3Y1.14%
Revenue growth 5Y8.78%
Sales Q2Q%5.64%
Revenue Next Year5.44%
Revenue Next 2Y5.6%
Revenue Next 3Y6.01%
Revenue Next 5Y7.27%
EBIT growth 1Y14.03%
EBIT growth 3Y-10.93%
EBIT growth 5Y12.66%
EBIT Next Year86.11%
EBIT Next 3Y30.34%
EBIT Next 5Y22%
FCF growth 1Y113.13%
FCF growth 3Y-7.69%
FCF growth 5Y25.62%
OCF growth 1Y31.31%
OCF growth 3Y-4.44%
OCF growth 5Y14.24%